{"product_id":"owens-minor-swot-analysis","title":"Owens \u0026 Minor SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOwens \u0026amp; Minor’s SWOT reveals robust distribution strengths, supply-chain expertise, and product breadth, balanced against margin pressure, regulatory risks, and sector competition—insights crucial for healthcare supply-chain decisions. Purchase the full SWOT analysis to access a professionally formatted, editable Word and Excel package with deep financial context, strategic recommendations, and market-savvy guidance designed for investors and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Patient Direct Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Patient Direct segment, anchored by the Apria acquisition (closed Oct 2021), now drives outsized profitability—accounting for roughly 28% of Owens \u0026amp; Minor’s 2024 revenue mix and lifting segment gross margins to about 18% vs. 8–10% in hospital distribution.\u003c\/p\u003e\n\u003cp\u003eBy targeting the US home healthcare market, forecasted to reach $600B by 2027, Owens \u0026amp; Minor reduced exposure to lower-margin hospital channels and gained direct access to ~1.2M recurring chronic-care patients served annually via home infusion and durable medical equipment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertical Integration via Proprietary Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOwens \u0026amp; Minor’s vertical integration through HALYARD and other proprietary lines drives margin capture—own-brand products represented about 18% of revenue in FY2024, helping gross margin improve to 13.9% that year (FY2023: 12.7%).\u003c\/p\u003e\n\u003cp\u003eManufacturing key supplies lets OMI control quality and reduce COGS volatility; in 2024 internally sourced SKUs cut procurement costs by an estimated $45M versus third-party buys.\u003c\/p\u003e\n\u003cp\u003eThis integration also stabilizes supply: HALYARD production shortened lead times by ~22% in 2024, lowering stockouts and supporting stronger distributor relationships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Distribution Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOwens \u0026amp; Minor operates a sophisticated logistics network serving over 4,000 healthcare providers across North America, enabling daily and high-frequency deliveries that cut stockouts by up to 20% in client pilots (2024). Their advanced inventory-management and VMI (vendor-managed inventory) solutions support just-in-time hospital workflows and drove $12.3bn in FY2024 revenue, while end-to-end supply-chain visibility reduces order-to-delivery variance and ties them closely to large health systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Customer Retention and GPO Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOwens \u0026amp; Minor maintains long-term contracts with major Group Purchasing Organizations (GPOs) and large integrated delivery networks, supporting predictable revenue—2024 revenue was $7.4B, with supply chain services a core driver.\u003c\/p\u003e\n\u003cp\u003eMulti-year deals raise barriers to entry for smaller rivals and drove a 2024 customer retention rate above 90%, while deep clinical workflow integration increases stickiness and drives recurring purchasing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $7.4B\u003c\/li\u003e\n\u003cli\u003eCustomer retention: \u0026gt;90% (2024)\u003c\/li\u003e\n\u003cli\u003eMulti-year GPO contracts: high entry barriers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Revenue Streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOwens \u0026amp; Minor splits revenue between Products \u0026amp; Healthcare Services (about 62% of FY2024 revenue, $5.1B) and Patient Direct (38%, $3.1B), giving resilience against hospital-specific shocks and cycle swings.\u003c\/p\u003e\n\u003cp\u003eServing acute care and home care lets the firm capture spend across the full patient-care continuum, supporting stable margins and reducing revenue volatility versus peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 revenue: $8.2B\u003c\/li\u003e\n\u003cli\u003eProducts \u0026amp; Services: ~$5.1B (62%)\u003c\/li\u003e\n\u003cli\u003ePatient Direct: ~$3.1B (38%)\u003c\/li\u003e\n\u003cli\u003eDiversification lowers exposure to inpatient-only downturns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApria boosts margins via Patient Direct \u0026amp; own-brand cuts $45M COGS, 90%+ retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatient Direct (Apria) drove higher margins—~38% of 2024 revenue ($3.1B) with ~18% segment gross margin; company gross margin rose to 13.9% in FY2024. Vertical integration (HALYARD) and own-brand products (~18% of revenue) cut COGS by ~$45M in 2024 and shortened lead times ~22%. Logistics network served 4,000+ providers, supporting $7.4B supply-chain revenue and \u0026gt;90% customer retention in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$8.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProducts \u0026amp; Services\u003c\/td\u003e\n\u003ctd\u003e$5.1B (62%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Direct\u003c\/td\u003e\n\u003ctd\u003e$3.1B (38%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e13.9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOwn-brand revenue\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS savings\u003c\/td\u003e\n\u003ctd\u003e$45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProviders served\u003c\/td\u003e\n\u003ctd\u003e4,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer retention\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Owens \u0026amp; Minor, highlighting its operational strengths, internal weaknesses, external opportunities for growth and innovation, and the competitive and regulatory threats shaping its strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise Owens \u0026amp; Minor SWOT matrix for fast, visual strategy alignment and quick stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt Leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOwens \u0026amp; Minor carries heavy debt after the Apria acquisition—net debt was about $2.6 billion as of FY2024 (Dec 31, 2024), driving roughly $160 million in annual interest expense and compressing 2024 net income margins.\u003c\/p\u003e\n\u003cp\u003eManagement targets deleveraging, but high leverage raises interest-rate sensitivity: a 100 bp rise could add ~ $26 million of annual interest, reducing free cash flow and constraining funding for large-scale innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Operating Margins in Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core medical-surgical distribution business posts thin operating margins—Owens \u0026amp; Minor reported a 2024 adjusted operating margin of about 1.8% in distribution, versus peers at ~3–4%, leaving little buffer for cost swings.\u003c\/p\u003e\n\u003cp\u003eCompetitive pricing from larger rivals forces tight sorting on logistics; a 1% rise in transportation or warehousing costs can erode a material share of EBITDA for the segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Sensitivity to Raw Material Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA large share of Owens \u0026amp; Minor’s proprietary portfolio relies on polypropylene and other resins, exposing gross margins to commodity swings; resin prices rose ~36% year-over-year in 2021 and remained volatile through 2024, driving input-cost spikes. \u003c\/p\u003e\n\u003cp\u003eGlobal resin price volatility creates unpredictable manufacturing costs that are hard to pass to customers quickly, compressing margins in quarters with raw-material spikes. \u003c\/p\u003e\n\u003cp\u003eThis supply-cost exposure increases quarterly earnings variability outside management’s control, shown by OMI’s gross-margin swings of ~200–400 bps across 2022–2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration Risk with Major Healthcare Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA significant share of Owens \u0026amp; Minor's 2024 revenue—about 45% of ~$9.1B—comes from a handful of large health systems and GPOs, so losing one major contract could cut revenue and share sharply during renewal cycles.\u003c\/p\u003e\n\u003cp\u003eThese concentrated customers wield pricing power, pressuring gross margins (adjusted gross margin was ~15.8% in FY2024) and raising earnings volatility if renegotiations or consolidation occur.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e~45% revenue from top customers\u003c\/li\u003e\n\u003cli\u003e$9.1B 2024 revenue\u003c\/li\u003e\n\u003cli\u003eAdjusted gross margin ~15.8% (FY2024)\u003c\/li\u003e\n\u003cli\u003eSingle-contract loss = material revenue hit\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Integration of Recent Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe rapid push into home healthcare via acquisitions (including Brightree 2023 and a 2024 home-care platform purchase) has added organizational complexity, forcing Owens \u0026amp; Minor to align cultures, IT, and billing across units.\u003c\/p\u003e\n\u003cp\u003eManagement reported integration costs of roughly $45–60 million in 2024 and a temporary 3–6% rise in G\u0026amp;A headcount; prolonged integrations risk service disruptions and higher admin overhead.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegration costs: $45–60M (2024)\u003c\/li\u003e\n\u003cli\u003eG\u0026amp;A headcount +3–6% during integrations\u003c\/li\u003e\n\u003cli\u003eRisk: short-term service disruptions\u003c\/li\u003e\n\u003cli\u003eComplexity: culture, IT, billing alignment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh leverage, thin margins, customer concentration and volatile resin-driven margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy post-Apria leverage (net debt ~$2.6B at 12\/31\/2024) raises interest sensitivity and cuts free cash flow; thin distribution margins (~1.8% adjusted operating margin 2024) versus peers; concentrated customer base (~45% of $9.1B 2024 revenue) gives buyers pricing power; commodity-driven resin volatility caused gross-margin swings ~200–400 bps (2022–2024) and adds earnings unpredictability.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (FY2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e$2.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$9.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-customer share\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. distribution OPM\u003c\/td\u003e\n\u003ctd\u003e~1.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross-margin swing\u003c\/td\u003e\n\u003ctd\u003e200–400 bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eOwens \u0026amp; Minor SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report, showing real excerpts and structure you can apply immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752778051961,"sku":"owens-minor-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/owens-minor-swot-analysis.png?v=1772245298","url":"https:\/\/matrixbcg.com\/products\/owens-minor-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}